Integrative Muscle-Adipose Score (IMAS): A Novel Unified, Sex-Sensitive Body Composition-Based Survival Predictor Enhancing Risk Stratification After Liver Transplantation.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42681570.
- Also identified by DOI 10.1097/SLA.0000000000007192.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the potential of integrating muscle and fat compartments into a novel and unified score for outcome prediction in a bicentric European cohort of LT recipients. Body composition (BC) reflects nutritional status and metabolic reserves and influences outcomes after orthotopic liver transplantation (LT). Validated tools for predicting long-term survival after LT remain scarce. Increasing evidence highlights sex-specific disparities in post-transplant outcomes. A total of 695 adult patients undergoing LT at Charité-Berlin (n=412, 2010 to 2020; discovery cohort) and University Hospital Aachen (n=283, 2010 to 2018; validation cohort) were included. CT-based BC was assessed at lumbar level 3/4. Muscle mass, quality, and adipose tissue were integrated into the integrative muscle-adipose score (IMAS) and correlated with survival and postoperative morbidity. Median follow-up was 54 (discovery) and 47 months (validation). A total of 31% of recipients were female. IMAS quartiles significantly stratified overall survival in both cohorts (P<0.01). Low IMAS was independently prognostic of overall survival in both cohorts. Sex-specific IMAS cutoffs were independently prognostic in both sexes (♂︎: HR=1.89, 95% CI: 1.37-2.70, P=0.001; ♀︎: HR=2.04, 95% CI: 1.17-3.55, P=0.012), whereas the BAR score failed to predict long-term survival in female recipients. Across sexes, low IMAS was associated with significantly lower restricted mean survival time at 5 years (♂︎ 43.2 vs. 50.16 mo, P<0.001; ♀︎ 44.2 vs. 51.71 mo, P=0.013) and a higher Comprehensive Complication Index 90 days after LT. The IMAS provides a novel, reproducible sex-sensitive framework for long-term outcome prediction after LT.